Last reviewed · How we verify
Glucoferron (FERROUS GLUCONATE)
Glucoferron, marketed by Sanofi, is an iron supplement primarily indicated for prenatal and postnatal folic acid supplementation, competing in a well-established market with other iron sources like ferrous fumarate and ferrous sulfate. Its key strength lies in its mechanism of replenishing iron stores effectively, supported by a key composition patent expiring in 2028. The primary risk to Glucoferron is the strong competition from generic alternatives, which have been on the market since 1946 and 1986, respectively.
At a glance
| Generic name | FERROUS GLUCONATE |
|---|---|
| Sponsor | Sanofi |
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
- Prenatal and Postnatal Folic Acid Supplementation
Common side effects
Drug interactions
- dolutegravir
- dolutegravir
- enoxacin
- enoxacin
- gatifloxacin
- levodopa
- levodopa
- levofloxacin
- levofloxacin
- levothyroxine sodium
- levothyroxine sodium
- lomefloxacin
Key clinical trials
- Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy (NA)
- South African Paediatric Surgical Outcomes Study 2 (PHASE4)
- The Efficacy of Minayo Iron-rich Yeast Drink With SOD on Female Nutritional Anemia, Skin Condition and Qi-blood Deficiency Syndrome (NA)
- The Efficacy of Minayo Iron-rich Nutritional Gummies on Female Anemia, Skin Condition and Qi-blood Deficiency Syndrome (NA)
- Nutritional Educational Program On Therapy in Iron Deficiency Anemia (NA)
- Iron Prehabilitation in Endometrial Cancer (PHASE4)
- Lactoferrin With Ferrous Gluconate Versus Ferrous Gluconate in Treatment of Iron Deficiency Anemia During Pregnancy (PHASE4)
- Strategies to Reduce Iron Deficiency (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucoferron CI brief — competitive landscape report
- Glucoferron updates RSS · CI watch RSS
- Sanofi portfolio CI